Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-009 with Chemotherapy in Advanced Solid Tumors and BTC
NCT04492033Phase 2Terminated
- Sponsor
- Handok
- Start
- Jun 2020
- Primary completion
- Jan 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tovecimig in solid tumor and biliary tract cancer (BTC) (3 arms), sponsored by Handok. Primary endpoints: Proportion of subjects with Dose-Limiting Toxicity and Objective Response Rate at 24 months. Started Jun 2020; status: terminated.
02
Drugs
tovecimig
03
Conditions
solid tumorbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04492033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492033.